FROM-16: ATMP
Research type
Research Study
Full title
Family Reported Outcomes in the Estimation of Societal Value of Advanced Therapy Medicinal Products (ATMPs)
IRAS ID
299383
Contact name
HAMISH LAING
Contact email
Sponsor organisation
Swansea University
Duration of Study in the UK
0 years, 6 months, 31 days
Research summary
Poor health, and its treatment, has impact beyond the healthcare system into wider society. A person's productivity, taxable earnings, benefit payments and community contribution may all be adversely affected by poor health. Family members living with or caring for a patient may suffer equally, or sometimes more than the patient themselves, but this familial burden has gone largely unrecognised by healthcare systems. The Family-Reported Outcome Measure (FROM-16) is the first generic questionnaire designed to measure the impact of any chronic disease on the quality of life of family members or partners of patients with a health condition.
Advance Therapy Medicinal Products (ATMPs) are a novel & ground-breaking therapeutic approach for curative treatment of disease and/or injury where conventional treatments have been ineffective. Such disease/injury generally has an extremely high impact on the patient’s quality of life, and also the quality of life of the patient’s family, in particular those family members who take on the role of ‘informal carer’.
ATMPs usually have very high costs and this can limit their usage, especially in the context of low prevalence disease and publicly-funded healthcare systems, where healthcare providers may be reluctant to take on the cost burden of the ATMP therapy. As a result, there is a particular focus on the ‘value’ of ATMPs. An important component of value is ‘Societal Value’, where a treatment leads to societal contributions, and considering Societal Value may justify the high cost of ATMPs despite the relatively few patients cured.
In this study, we will validate the FROM-16 for use as one measure of the Societal Value of very high cost, potentially curative treatments such as ATMPs.REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
21/YH/0228
Date of REC Opinion
9 Nov 2021
REC opinion
Further Information Favourable Opinion